PEDIATRICS Vol. 68 No. 4 October 1981, pp. 615-616
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berry, D. D.
Right arrow Articles by Box, Q. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, D. D.
Right arrow Articles by Box, Q. T.

Letters to the Editor

David D. Berry MD1, Ben H. Brouhard MD1, and Quellin T. Box MD1

1 Department of Pediatrics, University of Texas Medical Branch, Galveston, TX 77550

We appreciate Dr Liner's interest in our paper. We agree, as we stated in the paper, that lincomycin is not a first line drug and should be reserved for the patient population described in his letter.1 Furthermore, we certainly concur that the incidence of pseudomembranous colitis (PMC) following parenteral lincomycin is lese than 2%, in fact much less. If indeed the true incidence is 2%, then the probability of observing one or more cases of PMC in our series of 265 is 0.995, and thus the probability of observing no cases is 0.005.